Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Free Report)’s share price shot up 3.4% during trading on Thursday . The stock traded as high as $3.05 and last traded at $3.00. 15,229 shares were traded during trading, a decline of 83% from the average session volume of 89,974 shares. The stock had previously closed at $2.90.
Lixte Biotechnology Price Performance
The company has a 50 day moving average price of $2.45 and a 200 day moving average price of $3.92. The firm has a market cap of $6.75 million, a PE ratio of -0.91 and a beta of -0.39.
Insider Transactions at Lixte Biotechnology
In other news, CEO Der Baan Bastiaan Jeroen Van purchased 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was purchased at an average cost of $2.80 per share, with a total value of $28,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,000 shares of the company’s stock, valued at approximately $30,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 15.50% of the company’s stock.
Institutional Inflows and Outflows
Lixte Biotechnology Company Profile
Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.
- Five stocks we like better than Lixte Biotechnology
- What Do S&P 500 Stocks Tell Investors About the Market?
- Amazon, Target, Walmart in a race for fastest delivery
- Trading Stocks: RSI and Why it’s Useful
- Palo Alto Networks: the one security stock to rule them all
- The Significance of Brokerage Rankings in Stock Selection
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.